Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes.
cytokines
inflammation
low back pain
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
05
05
2021
accepted:
19
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
29
9
2021
Statut:
ppublish
Résumé
Low back pain (LBP) is a leading cause of disability worldwide, but the aetiology remains poorly understood. Finding relevant biomarkers may lead to better understanding of disease mechanisms. Patients with vertebral endplate bone marrow lesions visualised on MRI as Modic changes (MCs) have been proposed as a distinct LBP phenotype, and inflammatory mediators may be involved in the development of MCs. To identify possible serum biomarkers for LBP in patients with MCs. In this case control study serum levels of 40 cytokines were compared between patients with LBP and MC type 1 (n=46) or type 2 (n=37) and healthy controls (n=50). Analyses identified significantly higher levels of six out of 40 cytokines in the MC type 1 group (MC1), and five in the MC type 2 group (MC2) compared with healthy controls. Six cytokines were moderately correlated with pain. Principal component analyses revealed clustering and separation of patients with LBP and controls, capturing 40.8% of the total variance, with 10 cytokines contributing to the separation. Macrophage migration inhibitory factor (MIF) alone accounted for 92% of the total contribution. Further, receiver operating characteristics analysis revealed that MIF showed an acceptable ability to distinguish between patients and controls (area under the curve=0.79). These results suggest that cytokines may play a role in LBP with MCs. The clinical significance of the findings is unknown. MIF strongly contributed to clustering of patients with LBP with MCs and controls, and might be a biomarker for MCs. Ultimately, these results may guide future research on novel treatments for this patient group.
Sections du résumé
BACKGROUND
Low back pain (LBP) is a leading cause of disability worldwide, but the aetiology remains poorly understood. Finding relevant biomarkers may lead to better understanding of disease mechanisms. Patients with vertebral endplate bone marrow lesions visualised on MRI as Modic changes (MCs) have been proposed as a distinct LBP phenotype, and inflammatory mediators may be involved in the development of MCs.
OBJECTIVES
To identify possible serum biomarkers for LBP in patients with MCs.
METHODS
In this case control study serum levels of 40 cytokines were compared between patients with LBP and MC type 1 (n=46) or type 2 (n=37) and healthy controls (n=50).
RESULTS
Analyses identified significantly higher levels of six out of 40 cytokines in the MC type 1 group (MC1), and five in the MC type 2 group (MC2) compared with healthy controls. Six cytokines were moderately correlated with pain. Principal component analyses revealed clustering and separation of patients with LBP and controls, capturing 40.8% of the total variance, with 10 cytokines contributing to the separation. Macrophage migration inhibitory factor (MIF) alone accounted for 92% of the total contribution. Further, receiver operating characteristics analysis revealed that MIF showed an acceptable ability to distinguish between patients and controls (area under the curve=0.79).
CONCLUSIONS
These results suggest that cytokines may play a role in LBP with MCs. The clinical significance of the findings is unknown. MIF strongly contributed to clustering of patients with LBP with MCs and controls, and might be a biomarker for MCs. Ultimately, these results may guide future research on novel treatments for this patient group.
Identifiants
pubmed: 34344830
pii: rmdopen-2021-001726
doi: 10.1136/rmdopen-2021-001726
pmc: PMC8336134
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: LG has received honoraria from AbbVie, Boehringer Ingelheim, Celltrion, Novartis, Lilly, Orion Pharma, Pfizer, and Sandoz, outside the submitted work.
Références
Mol Pain. 2018 Jan-Dec;14:1744806918777401
pubmed: 29712506
Arthritis Rheumatol. 2017 Sep;69(9):1796-1806
pubmed: 28597514
J Pain Res. 2017 Jan 17;10:157-165
pubmed: 28176921
BMJ. 2009 Oct 06;339:b3829
pubmed: 19808766
Spine J. 2018 May;18(5):831-844
pubmed: 29253635
Spine J. 2014 Nov 1;14(11):2568-81
pubmed: 24534386
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Endocrinol Metab (Seoul). 2016 Sep;31(3):454-461
pubmed: 27469066
J Bone Joint Surg Br. 1994 Sep;76(5):757-64
pubmed: 8083266
Spine J. 2017 Jan;17(1):129-134
pubmed: 27497891
Bone. 2010 Aug;47(2):424-9
pubmed: 20471506
Radiology. 1988 Jan;166(1 Pt 1):193-9
pubmed: 3336678
Cytokine. 2015 Apr;72(2):135-45
pubmed: 25647268
Eur Spine J. 2016 Nov;25(11):3723-3734
pubmed: 26914098
Br J Biomed Sci. 2016 Jul;73(3):121-128
pubmed: 27476376
Spine (Phila Pa 1976). 2013 Nov 15;38(24):2118-23
pubmed: 23970112
Inflamm Res. 2015 Sep;64(9):721-31
pubmed: 26189947
Spine J. 2018 Nov;18(11):2140-2151
pubmed: 29960111
Lancet. 2017 Feb 18;389(10070):736-747
pubmed: 27745712
J Bone Joint Surg Br. 2002 Mar;84(2):196-201
pubmed: 11924650
Int J Mol Sci. 2020 May 27;21(11):
pubmed: 32471173
BMJ. 2019 Oct 16;367:l5654
pubmed: 31619437
Ann N Y Acad Sci. 2017 Dec;1410(1):68-84
pubmed: 29265416
PLoS One. 2018 Aug 1;13(8):e0200677
pubmed: 30067777
Neurosci Bull. 2021 Mar;37(3):339-352
pubmed: 33196963
Br J Pharmacol. 1992 Nov;107(3):660-4
pubmed: 1472964
Arthritis Res Ther. 2012 Sep 20;14(5):R199
pubmed: 22995428
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7849-54
pubmed: 8755565
J Orthop Res. 2016 Aug;34(8):1447-55
pubmed: 27101067
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11193-8
pubmed: 23776243
Expert Opin Ther Targets. 2010 Mar;14(3):253-64
pubmed: 20148714
Handb Exp Pharmacol. 2009;(194):417-49
pubmed: 19655114
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Clin Biochem. 2012 Jul;45(10-11):737-9
pubmed: 22449335
Arthritis Rheum. 2007 Oct 15;57(7):1311-5
pubmed: 17907216
Eur Spine J. 2016 Jan;25(1):207-216
pubmed: 25813008
Nat Rev Rheumatol. 2019 Jul;15(7):427-437
pubmed: 31197253
Lancet. 2018 Jun 9;391(10137):2356-2367
pubmed: 29573870
Eur J Pain. 2013 Jul;17(6):916-28
pubmed: 23208945
Arthritis Res Ther. 2015 Nov 21;17:334
pubmed: 26590032
Bone. 2014 Apr;61:91-101
pubmed: 24401612
Spine (Phila Pa 1976). 2006 Mar 15;31(6):623-31
pubmed: 16540864
J Neuroinflammation. 2016 Jun 07;13(1):141
pubmed: 27267059
Ann Intern Med. 1983 Dec;99(6):843-8
pubmed: 6651026
Behav Sci. 1974 Jan;19(1):1-15
pubmed: 4808738
J Interferon Cytokine Res. 1996 Sep;16(9):695-700
pubmed: 8887053
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3115-24
pubmed: 11124727
Clin Orthop Relat Res. 2014 Jun;472(6):1943-54
pubmed: 24569872
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436
Eur Spine J. 2021 Apr;30(4):1018-1027
pubmed: 33423134
Eur Spine J. 2017 May;26(5):1362-1373
pubmed: 28138783
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Sci Rep. 2019 Jul 10;9(1):10005
pubmed: 31292506
Pain. 1993 Feb;52(2):157-168
pubmed: 8455963
Acta Radiol Open. 2020 Jan 29;9(1):2058460120902402
pubmed: 32064122
Eur Spine J. 2008 Nov;17(11):1407-22
pubmed: 18787845
Skeletal Radiol. 2014 Sep;43(9):1271-9
pubmed: 24965739
Eur Spine J. 2018 May;27(5):1013-1020
pubmed: 28884220